Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Botensilimab |
Synonyms | |
Therapy Description |
Botensilimab (AGEN1181) is an antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Botensilimab | AGEN1181|AGEN 1181|AGEN-1181 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Botensilimab (AGEN1181) is an antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05529316 | Phase II | Botensilimab | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Suspended | USA | ITA | GBR | FRA | ESP | DEU | CHE | BRA | BEL | 1 |
NCT05608044 | Phase II | Balstilimab + Botensilimab Botensilimab | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Active, not recruiting | USA | ITA | FRA | ESP | BRA | BEL | 2 |
NCT03860272 | Phase I | Botensilimab | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | Recruiting | USA | GBR | 0 |